Thera-SAbDab

ROZANOLIXIZUMAB

>   Structural Summary
TherapeuticRozanolixizumab
TargetFCGRT
Heavy ChainEVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK
100% seqID Fv Structure6fgb [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedUCB
Conditions Approvedna
Conditions ActiveChronic inflammatory demyelinating polyradiculoneuropathy, Idiopathic thrombocytopenic purpura, Myasthenia gravis
Conditions DiscontinuedImmunological disorders
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]